Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany; Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany; Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mult Scler Relat Disord. 2022 Jul;63:103828. doi: 10.1016/j.msard.2022.103828. Epub 2022 Apr 25.
We performed a web-based survey among German-speaking neurologists to evaluate the acceptance of the 2021 German guideline in the diagnosis and treatment of multiple sclerosis. Based on 327 replies in total, the current survey largely reproduced the findings of an earlier, smaller survey on the prefinal consultation version of the guideline and confirmed high acceptance rates. Half of the participants were practising neurologists. Neurologists from MS centers with more than 500 patients per year (n=26) were more critical of the guideline. They reiterated some of the criticisms of the previous feedback, and, in particular, felt that safety aspects are overemphasized in the guideline, thereby superseding early aggressive therapy.
我们在德语国家的神经科医生中进行了一项网络调查，以评估他们对 2021 年德国多发性硬化症诊断和治疗指南的接受程度。总共收到了 327 份回复，本次调查基本再现了早期对指南最终草案预咨询版本的一项较小规模调查的结果，证实了其具有很高的接受度。其中一半的参与者是执业神经科医生。每年诊治超过 500 名患者的多发性硬化症中心的神经科医生（n=26）对该指南的批评更为尖锐。他们重申了之前反馈中的一些批评意见，尤其是认为该指南过分强调安全性，从而取代了早期的积极治疗。
